COGT (Cogent Biosciences) EPS (Basic): $-2.20 (TTM As of Mar. 2026)


COGT Cogent Biosciences Inc COGT
25 GF Score
Price $37.81
! 3 Warning Signs
View Full Analysis

What is Cogent Biosciences EPS (Basic)?

Cogent Biosciences COGT +4.13% 25 EPS (Basic) is $-2.20 as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Cogent Biosciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.53. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.20.

Cogent Biosciences's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.20.

Cogent Biosciences's EPS without NRI for the three months ended in Mar. 2026 was $-0.53. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cogent Biosciences  (NAS:COGT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cogent Biosciences EPS (Basic) Related Terms

Cogent Biosciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences EPS (Basic) Chart

Cogent Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.87 -1.73 -1.94 -1.94 -2.16

Cogent Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.53 -0.50 -0.64 -0.53
COGT
25GF Score
Cogent Biosciences Inc COGT
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogent Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cogent Biosciences's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-328.937-0)/128.899
=-2.55

Cogent Biosciences's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-97.352-0)/162.195
=-0.60

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-2.20 mean?
Cogent Biosciences (COGT) has a EPS (Basic) of $-2.20 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cogent Biosciences and its competitors.
Is Cogent Biosciences' EPS (Basic) too high?
Cogent Biosciences' current EPS (Basic) is $-2.20. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' EPS (Basic) compare to SRRK and RYTM?
Cogent Biosciences' EPS (Basic) of $-2.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current EPS (Basic) is $-2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current EPS (Basic) of $-2.20. The current EPS (Basic) is $-2.20. Cogent Biosciences' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current EPS (Basic) is $-2.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score

Get the complete analysis for COGT

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.81
Price